Gudui BioPharma

Gudui BioPharma is a Shanghai-based biotechnology company dedicated to discovering and developing small molecule therapeutics for traditionally "undruggable" targets. The company utilizes its proprietary G-Engine platform, which integrates structural biology, computational chemistry, and high-throughput screening to identify novel binding pockets on challenging proteins. Their research primarily focuses on high-value pathways in oncology and immunology, specifically targeting transcription factors and protein-protein interactions. Founded by industry veterans with experience at global pharmaceutical firms like Novartis and GSK, Gudui BioPharma aims to bridge the gap between basic science and clinical application. The company is supported by leading venture capital firms, including Qiming Venture Partners and Matrix Partners China, to advance its innovative pipeline toward clinical development.